多替阿巴拉米片（绥美凯）用药注意事项

(Suimeikai) is mainly used to treat adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV).

What are the precautions for taking Domitabalamid Tablets (Suimeikai)?

1. Immune reconstitution inflammatory syndrome: In severely immunodeficient patients infected with HIV, when starting combination antiretroviral therapy (CART), an inflammatory response may occur to asymptomatic or residual opportunistic pathogenic infections. Autoimmune disorders (e.g., Graves' disease) have also been reported; however, the reported timing of onset is inconsistent and these events may occur many months after initiation of treatment.

2. It is prohibited to be used in patients with known hypersensitivity to dolutegravir, abacavir, lamivudine or any excipients.

3. Chronic hepatitis B or hepatitis C co-infection: In the phase III study of dolutegravir, patients co-infected with hepatitis B and/or hepatitis C virus are allowed to be recruited, provided that during the baseline period, the liver function test value does not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients with hepatitis B and/or hepatitis C virus infection was similar to that in patients without hepatitis B or C virus infection, but the incidence of AST and ALT abnormalities was higher in the hepatitis B and/or hepatitis C infection subgroup across all treatment groups.

4. HLA-B5701 status must be confirmed before starting treatment with Dolutegra. In patients with positive HLA-B5701 status, or patients with negative HLA-B5701 status who had suspected abacavir hypersensitivity when previously receiving abacavir-containing treatment regimens, they should not be treated with Suimeike.

Recommended related hot articles: /newsDetail/82206.html